Metal-organic framework IRMOFs coated with a temperaturesensitive gel delivering norcantharidin to treat liver cancer

BACKGROUND Norcantharidin(NCTD)is suitable for the treatment of primary liver cancer,especially early and middle primary liver cancer.This compound can reduce tumors and improve immune function.However,the side effects of NCTD have limited its application.There is a marked need to reduce the side effects and increase the efficacy of NCTD.AIM To develop a nanomaterial carrier,NCTD-loaded metal-organic framework IRMOF-3 coated with a temperature-sensitive gel(NCTD-IRMOF-3-Gel),aiming to improve the anticancer activity of NCTD and reduce the drug dose.METHODS NCTD-IRMOF-3-Gel was obtained by a coordination reaction.The apparent characteristics and in vitro release of NCTD-IRMOF-3-Gel were investigated.Cell cytotoxicity assays,flow cytometry,and apoptosis experiments in mouse hepatoma(Hepa1-6)cells were used to determine the anti-liver cancer activity of NCTD-IRMOF-3-Gel in in vitro models.RESULTS The particle size of NCTD-IRMOF-3-Gel was 50-100 nm,and the particle size distribution was uniform.The release curve showed that NCTD-IRMOF-3-Gel had an obvious sustained-release effect.The cytotoxicity assays showed that the free drug NCTD and NCTD-IRMOF-3-Gel treatments markedly inhibited Hepa1-6 cell proliferation,and the inhibition rate increased with increasing drug concentration.By flow cytometry,NCTD-IRMOF-3-Gel was observed to block the Hepa1-6 cell cycle in the S and G2/M phases,and the thermosensitive gel nanoparticles may inhibit cell proliferation by inducing cell cycle arrest.Apoptosis experiments showed that NCTD-IRMOF-3-Gel induced the apoptosis of Hepa1-6 cells.CONCLUSION Our results indicated that the NCTD-IRMOF-3-Gel may be beneficial for liver cancer disease treatment.

Effects of Astragalus injection on chemokines, renal function and humoral immunity in patients with pulmonary tuberculosis

Objective:To investigate the effects of Astragalus Injection on inflammatory factors, chemokines, renal function and humoral immunity in patients with pulmonary tuberculosis. Methods:80 patients with pulmonary tuberculosis who were treated in the department of respiratory medicine in our hospital from October 2015 to October 2017 were randomly divided into control group and observation group, 40 cases in each group. Patients in the control group were given levofloxacin treatment;and patients in the observation group were given astragalus injection combined with levofloxacin treatment. Before and after treatment, procalcitonin (PCT), interferon-γ (INF-γ), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1 ), blood urea nitrogen (BUN), serum creatinine (SCr), uric acid (UA) and immunoglobulin (IgA, IgM, IgG) levels were measured and compared between the patients in the two groups.Result: After treatment, the levels of PCT, INF-γ, MCP-1 and MIP-1 in serum of the patients in the two groups were significantly decreased, and the levels of IgA, IgM and IgG were significantly increased. The changes of the PCT, INF-γ, MCP-1, MIP-1 , IgA, IgM and IgG of patients in the observation group were significantly stronger than those in the control group (P<0.05). After treatment, the levels of BUN, SCr and UA in serum of patients in the two groups increased significantly. The serum levels of above indexes of patients in the observation group were significantly lower than those in the control group (P<0.05).Conclusion: Astragalus injection can significantly relieve the inflammatory state of patients with pulmonary tuberculosis, reduce the level of chemokines, enhance the renal function and immune function of patients. It has good clinical efficacy.